Mothaffar Rimawi
Expertise in
6
conditions

Dr. Mothaffar Rimawi

Hematology Oncology | Oncology
Baylor College Of Medicine
6720 Bertner Ave, 
Houston, TX 
Accepting New Patients
Expertise in
6
conditions
Baylor College Of Medicine
6720 Bertner Ave, 
Houston, TX 

Overview

Dr. Mothaffar F. Rimawi is a board-certified medical oncologist specializing in breast cancer care and research. He is Professor at the Department of Medicine, Section of Hematology and Oncology at Baylor College of Medicine. Dr. Rimawi is also Executive Medical Director & Associate Director of Clinical Affairs and Co-Leader of the Breast Cancer Program at BCM’s Dan L Duncan Comprehensive Cancer Center. Additionally, he serves as Chief of the Oncology Service Line at St Luke's Health in Houston.Dr. Rimawi’s professional interests include: the diagnosis, treatment and management of breast cancer; clinical trials in breast cancer; neoadjuvant therapy; targeted therapy and biomarkers in breast cancer; treatment resistance to ER and HER2-targeted therapies in breast cancer; locally advanced breast cancer; and breast disease and cancer.Dr. Rimawi received his medical degree from the University of Jordan in Amman, Jordan. He completed his residency in Internal Medicine and fellowships in Medical Oncology and Hematology and Breast Cancer at BCM. Dr. Rimawi holds certifications in Internal Medicine and Medical Oncology from the American Board of Internal Medicine. He is a member of the American College of Physicians, American Society of Clinical Oncology and the American Medical Association.In addition to English, Dr. Rimawi speaks Arabic.

Dr. Rimawi is highly rated in 6 conditions, according to our data. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Paget Disease of the Breast.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

The University Of Jordan Faculty Of Medicine - Jordan

Residency

Residency at Baylor College Of Medicine 08/ - Houston, Texas United States - 2001

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in TX

Fellowships

Internal Medicine Fellowship at Baylor College Of Medicine 11/ - Houston, Texas United States - 2004
Medical Oncology and Hematology Fellowship at Baylor College Of Medicine 05/ - Houston, Texas United States - 2005

Hospital Affiliations

Baylor St. Luke's Medical Center - Houston, TX

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

BAYLOR COLLEGE OF MEDICINE
6720 Bertner Ave, Houston, TX 77030
Other Locations
BAYLOR COLLEGE OF MEDICINE
2525 A Holly Hall St, Unit 3c, Houston, TX 77054
BAYLOR COLLEGE OF MEDICINE
7200 Cambridge St, Houston, TX 77030
BAYLOR COLLEGE OF MEDICINE
1504 Taub Loop, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drugs: ESTRING, Replens
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Study Phase: Phase 2
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation
Study Drugs: Aromatase Inhibition Therapy, Carboplatin, Docetaxel, Goserelin Acetate, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer
A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2025
Intervention Type: Drug
Study Drug: Simvastatin
Study Phase: Phase 2
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors
A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors
Enrollment Status: Completed
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Abraxane
Study Phase: Phase 1/Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug, Other
Study Drugs: Enzalutamide, Taselisib
Study Phase: Phase 1/Phase 2
NSABP Biospecimen Discovery Project
NSABP Biospecimen Discovery Project
Enrollment Status: Unknown
Publish Date: October 05, 2021
Intervention Type: Biological, Drug
A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer
A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer
Enrollment Status: Terminated
Publish Date: September 18, 2014
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 20 Less Clinical Trials

107 Total Publications

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Journal: The New England journal of medicine
Published: October 29, 2025
Similar Doctors
Hagop Kantarjian
Expertise in
47
conditions
Dr. Hagop Kantarjian
Oncology
Expertise in
47
conditions
Dr. Hagop Kantarjian
Oncology

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.1 miles away)
713-792-2813
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist in Houston, Texas. Dr. Kantarjian is highly rated in 47 conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Naval Daver
Expertise in
40
conditions
Dr. Naval Daver
Oncology
Expertise in
40
conditions
Dr. Naval Daver
Oncology

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.1 miles away)
713-794-4392
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is an Oncologist in Houston, Texas. Dr. Daver is highly rated in 40 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
28
conditions
Dr. Neeta Somaiah
Oncology
Expertise in
28
conditions
Dr. Neeta Somaiah
Oncology

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.2 miles away)
713-792-8850
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neeta Somaiah is an Oncologist in Houston, Texas. Dr. Somaiah is highly rated in 28 conditions, according to our data. Her top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Hepato-Pancreato-Biliary Surgery.

Frequently Asked Questions about Dr. Mothaffar Rimawi

How do I make an appointment with Dr. Mothaffar Rimawi?

You can book an appointment with Dr. Mothaffar Rimawi by calling their office at 713-526-4243. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mothaffar Rimawi a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mothaffar Rimawi is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mothaffar Rimawi specialize in?

While Dr. Mothaffar Rimawi is a Hematology Oncology, they have specific expertise in Breast Cancer, HER-2 Positive Breast Cancer, and Triple-Negative Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Mothaffar Rimawi participate in research or clinical trials?

Yes. Dr. Mothaffar Rimawi has published 107 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Mothaffar Rimawi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mothaffar Rimawi accept my insurance?

Dr. Mothaffar Rimawi accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 713-526-4243 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rimawi's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile